• A clinical-stage gene therapy company, similar to an early Spark Therapeutics (a gene therapy pioneer now part of Roche), developing treatments for conditions like inherited blindness and Parkinson's.
• A biotech firm dedicated to solving inherited and neurodegenerative diseases through gene therapy, much like a clinical-stage version of Sarepta Therapeutics or bluebird bio in their early days.
• An integrated gene therapy developer, building its own treatments for a range of serious conditions from inherited eye diseases to Parkinson's, akin to how uniQure operates.

• Botaretigene sparoparvovec (Lumevoq): A clinical-stage gene therapy candidate designed to treat X-linked retinitis pigmentosa (XLRP), an inherited retinal disease causing progressive vision loss.
• Achromatopsia Gene Therapies: Gene therapy programs targeting inherited retinal diseases caused by mutations in CNGB3 and CNGA3, which lead to severe vision impairment.
• Parkinson's Disease Gene Therapy: A clinical-stage gene therapy program investigating treatments for Parkinson's disease by delivering genes that produce key neurotrophic factors or enzymes in the brain.
• Radiation-induced Xerostomia Gene Therapy: A gene therapy program aimed at restoring normal salivary gland function in patients suffering from severe dry mouth as a result of radiation treatment for head and neck cancer.

MeiraGTx (MGTX) is a clinical-stage gene therapy company focused on the research and development of treatments, not the commercial sale of approved products to end-users or a broad customer base. As such, it does not have traditional "customers" in the way a commercial company does.

Its revenue primarily stems from strategic collaboration agreements with larger pharmaceutical companies. In this context, its major "customer" or partner is:

• Janssen Pharmaceuticals, Inc., a subsidiary of **Johnson & Johnson** (symbol: JNJ).

Janssen Pharmaceuticals, Inc. is responsible for a significant portion, if not all, of MeiraGTx's collaboration revenue, particularly related to the development and commercialization of certain gene therapies.

• Advanced BioScience Laboratories, Inc.
• Cytiva (part of Danaher Corporation, Symbol: DHR)
• Thermo Fisher Scientific Inc. (Symbol: TMO)

Alexandria Forbes, Ph.D. President and Chief Executive Officer

Dr. Alexandria Forbes has served as President, Chief Executive Officer, and a member of the board of directors of MeiraGTx since March 2015, and she co-founded the company in 2015. Before co-founding MeiraGTx, Dr. Forbes was Senior Vice President of Commercial Operations at Kadmon Holdings, Inc., a biopharmaceutical company, from September 2013 to April 2015. She spent eleven years as a healthcare investor, including roles at Sivik Global Healthcare from September 2000 to November 2008, and Meadowvale Asset Management, a healthcare hedge fund, from January 2010 to June 2012. Her career began as an academic, holding a Ph.D. in Molecular Genetics from the University of Oxford.

Richard Giroux Chief Operating Officer and Chief Financial Officer

Richard Giroux has served as Chief Operating Officer of MeiraGTx since March 2015 and assumed the role of Chief Operating Officer & Chief Financial Officer in April 2019. Prior to joining MeiraGTx, Mr. Giroux was a partner at Sarissa Capital Management LP, an activist healthcare hedge fund, from March 2014 to March 2015. Earlier, from January 2010 to June 2012, he was a founding partner and healthcare portfolio manager at Meadowvale Partners, a multi-strategy hedge fund. His background primarily involves leadership roles within healthcare-focused hedge funds.

Stuart Naylor, Ph.D. Chief Development Officer

Dr. Stuart Naylor has served as Chief Development Officer of MeiraGTx since April 2015. His previous roles include serving as Chief Executive Officer of Athena Vision, a biotechnology company, from April 2015 to April 2016. From June 2013 to April 2015, Dr. Naylor was the managing director of Coltivare Ltd., a healthcare consulting company, and prior to that, he was Executive Director and Chief Scientific Officer of Oxford BioMedica plc, a gene therapy company, from 2008 to 2013.

Robert K. Zeldin, M.D. Chief Medical Officer

Dr. Robert Zeldin has served as Chief Medical Officer of MeiraGTx since August 2020, bringing over two decades of clinical, regulatory, and industry experience. He previously held the Chief Medical Officer position at Acceleron Pharma, where he was instrumental in the preparation of a biologics license application for luspatercept, and also served as CMO of Immunovant. Before his industry career, Dr. Zeldin worked as a Medical Officer at the U.S. Food & Drug Administration's Center for Biologics Evaluation and Research.

Robert Wollin, JD General Counsel and Secretary

Robert Wollin serves as the General Counsel and Secretary for MeiraGTx.

1. Financial Instability and Dependence on Future Funding: MeiraGTx is a clinical-stage company with a history of significant losses and has not yet achieved profitability or consistent revenue generation. The company's financial health is poor, as indicated by a low Piotroski F-Score and negative free cash flow, with an Altman Z-Score suggesting a high risk of bankruptcy within the next two years. Continuous funding is required to support its extensive research and development activities and advance its pipeline.
2. Clinical Trial Outcomes and Regulatory Approvals: The success of MeiraGTx is heavily dependent on its gene therapy candidates successfully progressing through clinical trials and ultimately receiving regulatory approvals from bodies like the FDA. There is inherent uncertainty in clinical trial outcomes, and failure at any stage of development or inability to obtain timely regulatory approvals for its product candidates would significantly impact the company's future performance and ability to commercialize its therapies.
3. Uncertainty Regarding Priority Review Vouchers: MeiraGTx faces a specific regulatory risk related to the uncertain outcome of obtaining priority review vouchers for its gene therapy candidates designated for rare pediatric diseases. While the FDA has granted these designations, there is no guarantee that eventual FDA approvals will result in the receipt of these valuable vouchers, which can be crucial for accelerating the review of future product applications and influencing the company's strategic planning and resource allocation. There is also an impending deadline of September 2026 for obtaining FDA approval to secure a voucher, unless Congress extends the statutory dates.

The increasingly intense competition in the inherited retinal disease (IRD) gene therapy market, particularly for X-linked retinitis pigmentosa (XLRP) and achromatopsia, poses a clear emerging threat to MeiraGTx. This heightened competitive pressure is undermining the attractiveness of MeiraGTx's IRD programs to potential partners, which is critical for their continued development following the company's strategic decision to seek external funding and collaboration for these assets.

MeiraGTx (MGTX) has several main products in its pipeline, with addressable market sizes identified for the following:

• Parkinson's Disease (AAV-GAD):
  • Patient Population: Approximately one million Americans and 10 million people worldwide.
  • Market Size: The global Parkinson's disease treatment market size was estimated at USD 5.65 billion in 2024 and is projected to reach USD 7.58 billion by 2030, with a Compound Annual Growth Rate (CAGR) of 5.04% from 2025 to 2030. North America accounted for 38.03% of this market in 2024.
• X-Linked Retinitis Pigmentosa (XLRP) / botaretigene sparoparvovec (bota-vec):
  • Patient Population: Approximately 16,500 cases in 2023 across the 7 Major Markets (7MM) including the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan. Specifically, there are an estimated 20,000 XLRP-RPGR patients in the U.S., Japan, and EU5 (Germany, France, Spain, Italy, and the UK). Globally, XLRP is estimated to affect around 1 in 100,000 to 200,000 people.
  • Market Size: The global XLRP therapeutic market is anticipated to experience a CAGR of approximately 7-10% from 2024 to 2030. The total Retinitis Pigmentosa Treatment Market Size across the 7MM was approximately USD 500 million in 2023.
• Achromatopsia (AAV-CNGB3 and AAV-CNGA3):
  • Patient Population: Achromatopsia (ACHM) occurs in approximately one in 30,000 people in the United States.
  • Market Size: The global Achromatopsia market size was estimated at USD 108.24 million in 2024 and is expected to reach USD 114.64 million in 2025. It is projected to grow at a CAGR of 5.90% to reach USD 171.22 million by 2032. Across the top 7 markets (U.S., EU4, UK, and Japan), the market reached USD 111.5 million in 2024 and is expected to reach USD 187.8 million by 2035, exhibiting a CAGR of 4.84% during 2025-2035.

For the following products, specific addressable market sizes in USD were not readily available in the search results:

• AIPL1-associated Leber Congenital Amaurosis 4 (LCA4) (AAV-AIPL1): null
• Radiation-Induced Xerostomia (RIX) (AAV-AQP1): null
• RPE65-associated retinal dystrophy (AAV-RPE65): null

MeiraGTx (MGTX) has several anticipated drivers for future revenue growth over the next two to three years:

1. Hologen Partnership and AAV-GAD Program Advancement: The strategic collaboration with Hologen AI, established in March 2025, is a significant revenue driver. MeiraGTx received an upfront cash payment of $200 million (with $23 million received as of Q2 2025) and the joint venture, Hologen Neuro AI Ltd, will receive up to an additional $230 million from Hologen to fully fund the development of AAV-GAD for Parkinson's disease through commercialization. MeiraGTx retains 30% ownership in the joint venture and will lead clinical development and manufacturing, entering into exclusive clinical and commercial manufacturing supply agreements.
2. Commercialization of AAV-AQP1 for Radiation-Induced Xerostomia: The company's AAV-AQP1 program is in pivotal Phase 2 trials with a Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA, and MeiraGTx anticipates filing a Biologics License Application (BLA) by 2026. This represents a potential new product launch into the market. Sanofi also holds a Right of First Negotiation for this Phase 2 program.
3. Milestone Payments from Johnson & Johnson for Bota-Vec: MeiraGTx sold the rights to its Bota-Vec program for X-Linked Retinitis Pigmentosa (XLRP) to Johnson & Johnson. As part of this agreement, MeiraGTx is eligible to receive up to $285 million upon the first commercial sales of Bota-Vec in the U.S. and EU, in addition to payments for manufacturing technology transfer.
4. Third-Party GMP Manufacturing Services: MeiraGTx possesses end-to-end Good Manufacturing Practice (GMP) capabilities. The company is exploring the potential to add a revenue stream by offering its GMP manufacturing services to third parties. Hologen's agreement to fund a portion of MeiraGTx's manufacturing operations and take a minority stake in a manufacturing subsidiary further underscores the value of these capabilities.
5. Progression and Potential Monetization of Other Pipeline Assets: Beyond the lead programs, MeiraGTx continues to advance other gene therapy candidates. These include AAV-AIPL1 for congenital blindness, which is moving towards exceptional-circumstances filings and has a planned U.S. BLA, and AAV-BDNF for genetic obesity, which is also receiving funding through the Hologen Neuro AI joint venture. Future partnerships, milestone payments, or successful commercialization of these or other preclinical programs could contribute to revenue growth.

Share Issuance

• In August 2024, MeiraGTx priced an underwritten offering of 12,500,000 ordinary shares at $4.00 per share, generating $50 million in gross proceeds.
• As of July 31, 2025, the company had 80,447,477 ordinary shares outstanding.
• The number of outstanding shares was 80,585,625 at the end of 2025.

Inbound Investments

• MeiraGTx entered into a strategic collaboration with Hologen AI, which includes a $200 million upfront payment and the formation of a joint venture, Hologen Neuro AI Ltd, with an additional $230 million committed capital from Hologen for the development of AAV-GAD for Parkinson's disease.
• Sanofi made a $30 million equity investment in MeiraGTx as part of an ordinary share offering in August 2024.
• The company received a $50.0 million milestone payment in the first quarter of 2024 from Janssen related to an asset purchase agreement.

Outbound Investments

• MeiraGTx has not made any investments or acquisitions.

Capital Expenditures

• MeiraGTx operates five manufacturing facilities globally, including two licensed for GMP viral vector production and a GMP QC facility with clinical and commercial licensure.
• Its wholly-owned gene therapy manufacturing facility in Shannon, Ireland, received Commercial MIA Authorization for QC Testing in the second quarter of 2023, making it the first gene therapy manufacturing site in Ireland to receive such a commercial license.
• As of December 31, 2024, MeiraGTx expects to have sufficient capital to fund capital expenditure requirements into 2027, factoring in the proceeds from the Hologen collaboration.